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Abstract: The clinical outcome of allogeneic hematopoietic stem cell transplantation (SCT) may be
influenced by the metabolic status of the recipient following conditioning, which in turn may enable
risk stratification with respect to the development of transplant-associated complications such as
graft vs. host disease (GVHD). To better understand the impact of the metabolic profile of transplant
recipients on post-transplant alloreactivity, we investigated the metabolic signature of 14 patients
undergoing myeloablative conditioning followed by either human leukocyte antigen (HLA)-matched
related or unrelated donor SCT, or autologous SCT. Blood samples were taken following conditioning
and prior to transplant on day 0 and the plasma was comprehensively characterized with respect
to its lipidome and metabolome via liquid chromatography/mass spectrometry (LCMS) and gas
chromatography/mass spectrometry (GCMS). A pro-inflammatory metabolic profile was observed in
patients who eventually developed GVHD. Five potential pre-transplant biomarkers, 2-aminobutyric
acid, 1-monopalmitin, diacylglycerols (DG 38:5, DG 38:6), and fatty acid FA 20:1 demonstrated high
sensitivity and specificity towards predicting post-transplant GVHD. The resulting predictive model
demonstrated an estimated predictive accuracy of risk stratification of 100%, with area under the curve
of the ROC of 0.995. The likelihood ratio of 1-monopalmitin (infinity), DG 38:5 (6.0), and DG 38:6
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(6.0) also demonstrated that a patient with a positive test result for these biomarkers following
conditioning and prior to transplant will be at risk of developing GVHD. Collectively, the data suggest
the possibility that pre-transplant metabolic signature may be used for risk stratification of SCT
recipients with respect to development of alloreactivity.
Keywords: stem cell transplantation; graft vs. host disease; risk stratification; metabolomics; lipidomics

1. Introduction
Transplantation of hematopoietic progenitors from an HLA-matched donor is a curative procedure
for many patients with hematologic malignancies and disorder of hematopoiesis. Graft vs. host disease
(GVHD) is a frequently observed complication of stem cell transplantation (SCT), which contributes
to transplant-related mortality and adversely impacts clinical outcomes following transplantation.
GVHD after allogeneic hematopoietic stem cell transplantation (HSCT) is a reaction of donor immune
cells to recipient tissues. An inflammatory cascade triggered by the preparative regimen causes
activated donor T cells to target and destroy epithelial cells. About 35–50% of HSCT recipients will
develop acute GVHD. It is mediated by donor-derived T cells responding to minor histocompatibility
antigens encountered in the recipient. The T cells encounter these alloantigens, undergo activation,
and perform functions such as cytokine secretion (IL-2, IL-4, IL-10, IL-12, IL-17, and interferon gamma
by helper T cell subsets) and target lysis (granzyme and perforin secretion by cytotoxic T cells). These
functions are accompanied by significant metabolic adaptations in the T cells, including increased
glycolysis and oxygen consumption as well as cytokine production [1]. As an example, higher levels
of GLUT 1 (glucose transporter 1) expression have been observed in activated T cells, suggesting
increased metabolic and biosynthetic rates [2]. Supporting this, correlation has been shown between
intracellular ATP concentration in T cells and severity of clinical GVHD in humans, and between
increasing glycolysis and GVHD in murine models [3,4]. These observations suggest that donor T cell
activation and consequent metabolic and biosynthetic changes may correlate with clinical events as
immune reconstitution occurs following SCT, and alloreactivity is triggered.
Just as metabolic changes in the T cell are crucial to the onset of immune reactions, the metabolic
milieu in which the T cells find themselves influences their function. In this respect, the lipid molecules
constitute a family of important functional mediators. The effects of some lipid molecules on the
T cells have been studied recently. These effects include lysophosphatidylserine (lysoPS)-mediated
suppression of IL-2 production and suppression of T cell proliferation [5]. This effect is mediated via
LPS3/G protein coupled receptor 174, which triggers IL-2 production in CD4+ T cell. Another enzyme,
acid sphingomyelinase (ASMase), generates ceramide and modulates signaling cascades involving
CD3 and CD28. It is involved in Th1 and Th17 responses through its effect on signal transducer and
activator of transcription 3 (STAT 3) and the mammalian target of rapamycin (mTOR) [6]. An acid
sphingomyelinase deficient mouse model experiences attenuation of GVHD [7]. Along the same
lines, leukotriene C4 has been shown to be important for airway inflammation when administered
to murine models along with IL33 [8]. Consistent with such results are the observations that T cells
in acetyl-CoA carboxylase deficient mice are resistant to induction of GVHD [9]. T effector cells
have been shown to increase their reliance on fatty acid metabolism during GVHD as well [10,11],
for example, Prostaglandin E2 (PGE2 ) has been implicated in modulating T cell effects of mesenchymal
stromal cells on T cell populations [12] and PGE2 priming of T cells reduces GVHD when localized
to the site of alloreactivity [13]. Further, bone marrow stromal cells also exert an ameliorating
influence on GVHD through indoleamine 2,3-dioxygenase (IDO) and PGE2 expression [14]. These
lipid-mediated effects have been targeted in the treatment of GVHD, for instance, the effectiveness of
leukotriene inhibitor monteleukast has long been recognized in managing GVHD of the lung [15,16].
Additionally, prostaglandins have been studied in GVHD prevention strategies [17], particularly
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PGE2 [13]. A leukotriene inhibitor, eicosapentanoic acid (EPA), has also been studied in the treatment
of GVHD as well as prophylaxis [18,19]. Prostaglandin mediators FT1050 (16,16-dimethyl PGE2) and
FT4145 (dexamethasone) are also being studied in clinical trials of GVHD prophylaxis using ex-vivo
modification of the allograft [20,21]. These observations make it crucial to gain an understanding
regarding the lipid and metabolic changes that come about following dose-intensive myeloablative
conditioning, and how the ensuing metabolome and the lipidome might impact T cell function
following SCT. Modern methods of lipidomics and metabolomics allow us to study such changes in
detail [22–26]. In this paper, we describe the lipidomic and metabolomic profiles of patients undergoing
myeloablative conditioning and stem cell transplantation and try to understand the role of these
metabolites in mediating alloreactivity, and for potentially predicting GVHD.
2. Materials and Methods
2.1. Patients
Patients were enrolled prospectively in a Virginia Commonwealth University (VCU) Institutional
Review Board (IRB)-approved observational pilot study; patients provided written informed consent
prior to enrollment (Ethical code: 45 CFR 46.108(b) and 45 CFR 46.109(e) and 45 CFR 46.110 by VCU IRB
Panel A, permission date: 27 March 2019). Patients underwent myeloablative conditioning followed
by either HLA-matched related (MRD), or HLA-matched unrelated donor (URD); patients undergoing
autologous stem cell transplantation (auto) were also included as controls (Table 1). HLA matching
was at the allelic level; allogeneic HCT recipients received ATG, calcineurin inhibitors, and either
mycophenolate mofetil or methotrexate for GVHD prophylaxis. Blood samples were drawn after
completion of myeloablative conditioning therapy on day 0 prior to SCT. Blood was processed for
plasma collection and frozen at −80 ◦ C until mass spectroscopy-based metabolomic and lipidomic
analysis. Given the small patient cohort, acute and chronic GVHD data were pooled, and Glucksberg
and NIH Consensus criteria were used to diagnose and stage GVHD.
Table 1. Demographic data for the cohort study.
Donor
Type

Age

Gender

Race

BMI

Prep Regimen;
GVHD Prophylaxis

Disease

GVHD
(Grade/Severity)

GVHD
Organs/System

MRD

60

Female

C

21.41

Bu/Cy; Cyls/MTX

MDS

Acute (1)

Skin, liver, GI

URD

50

Female

C

24.42

Bu/Cy; Tac/MMF

AML *

Acute (4)

Skin, GI

URD

31

Female

C

34.99

Bu/Cy; Tac/MTX

AML

Chronic (mod)

Skin, GI

URD

40

Female

C

42.08

TBI/Cy; Tac/MTX

ALL

Acute (2)

GI

URD

57

Male

C

22.09

Bu/Flu; Tac/MMF

MDS

Acute (2)

Skin

URD

50

Male

C

26.13

Flu/Mel; Tac/MTX

ALL

Acute (1)

Skin

MRD

59

Male

C

21.80

Bu/Flu; Cyls/MMF

MDS

Chronic (mod)

Oral, GI

URD

50

Female

C

28.85

Bu/Cy; Tac/MTX

CML &

no

-

MRD

63

Female

C

27.81

Bu/Flu; Cyls/MTX

ET #

no

-

URD

66

Male

C

29.45

Flu/Mel; Tac/MMF

MCL

no

-

auto

48

Female

C

17.60

BEAM; n/a

PTCL

n/a

-

auto

35

Female

AA

25.04

Mel 200; n/a

MM

n/a

-

auto

44

Male

AA

45.22

BEAM; n/a

NHL

n/a

-

auto

40

Male

AA

51.22

BEAM; n/a

ALL

n/a

-

BMI = Body Mass Index; MRD = match related donor; URD = unrelated donor; auto = autologous; C = Caucasian;
AA = African American; HTN = hypertension; MI = myocardial infarction; n/a = not applicable. Bu = Busulfan;
Cy = Cytoxan; Cyls = cyclosporine; MTX = methotrexate; Tac = tacrolimus; MMF = mycopehnolate mofetil;
TBI = total body irradiation; Flu = fludarabine; Mel = melphalan; BEAM = carmustine, etoposide, cytarabine and
melphalan; MDS = myelodysplasia; AML = acute myeloid leukemia; HL = Hodgkin lymphoma; CML = chronic
myeloid leukemia; ET = essential thrombocythemia; MCL = mantle cell lymphoma; PTCL = Peripheral T-cell
lymphoma NOS; MM = multiple myeloma; NHL = non-Hodgkin lymphoma; ALL = acute lymphoblastic leukemia;
GI = gastrointestinal system * Secondary to chemotherapy; & blast crisis; # w/progression to myelofibrosis.
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2.2. Lipid and Metabolite Extraction for LC-MS/MS Analyses
Blood plasma lipids extraction was carried out using a biphasic solvent system of cold methanol,
methyl tertiary butyl ether (MTBE), and water with some modifications (Matyash et al., 2008).
In detail, 225 µL of cold methanol containing a mixture of odd chain and deuterated lipid
internal standards [lysoPE(17:1), lysoPC(17:0), PC(12:0/13:0), PE(17:0/17:0), PG(17:0/17:0), sphingosine
(d17:1), d7 cholesterol, SM(17:0), C17 ceramide, d3 palmitic acid, MG(17:0/0:0/0:0), DG(18:1/2:0/0:0),
DG(12:0/12:0/0:0), and d5 TG(17:0/17:1/17:0)] were added to a 20 µL blood plasma aliquot in a 1.5 mL
polypropylene tube and then vortexed. Next, 750 µL of cold MTBE was added, followed by vortexing
and shaking with an orbital mixer. Phase separation was induced by adding 188 µL of MS-grade
water. Upon vortexing (20 s), the sample was centrifuged at 12,300 rpm for 2 min. The upper organic
phase was collected in two 300 µL aliquots and evaporated with a vapor trap. Dried extracts were
resuspended using 110 µL of a methanol/toluene (9:1, v/v) mixture containing CUDA (50 ng/mL;
internal standard for quality control of injection) with support of vortexing (10 s), and centrifuged at
800 rpm for 5 min, followed by transferring 100 µL of the supernatant into auto-sampler vial with an
insert. The lower polar layer was collected and an aliquot of 125 µL was evaporated to dryness in a
SpeedVac, and resuspended in acetonitrile for polar metabolite analysis via HILIC LC-MS/MS method.
2.3. Metabolomics: GC-MS Metabolite Extraction
A total of 30 µL of plasma sample was added to a 1.0 mL of pre-chilled (−20 ◦ C) extraction solution
composed of acetonitrile, isopropanol, and water (3:3:2, v/v/v). Samples were vortexed and shaken for
5 min at 4 ◦ C using the orbital mixing chilling/heating plate. Next, the mixture was centrifuged for
2 min at 14,000 rcf. Then, 450 µL of the supernatant was dried with cold trap concentrator. The dried
aliquot was then reconstituted with 450 µL acetonitrile:water (50:50) solution and centrifuged for 2 min
at 14,000 rcf. The supernatant was transferred to a polypropylene tube, and subjected to drying in a
cold trap. The process of derivatization began with the addition of 10 µL of 40 mg/mL Methoxyamine
hydrochloride solution to each dried sample and standard. Samples were shaken at maximum speed
at 30 ◦ C for 1.5 h. Then, 91 µL of MSTFA + FAME mixture was added to each sample and standard,
and capped immediately. After shaking at maximum speed at 37 ◦ C, the content was transferred to
glass vials with micro-inserts inserted and capped immediately.
2.4. Lipids: LC-MC/MC Conditions
Untargeted lipid analysis was undertaken with Sciex TripleTOF 6600 coupled to Agilent 1290 LC.
Lipids were separated on an Acquity UPLC CSH C18 column (100 × 2.1 mm; 1.7 µm) (Waters, Milford,
MA, USA). The column was maintained at 65 ◦ C and the flow-rate of 0.6 mL/min. The mobile phases
consisted of (A) 60:40 (v/v) acetonitrile:water with 10 mM ammonium acetate and (B) 90:10 (v/v)
isopropanol:acetonitrile with 10 mM ammonium acetate. The separation was conducted following a
stepwise gradient: 0–2 min 15–30% (B), 2–2.5 min 48% (B), 2.5–11 min 82% (B), 11–11.5 min 99% (B),
11.5–12 min 99% (B), 12–12.1 15% (B), and 12–14 min 15% (B). Negative and positive electrospray
ionization (ESI) modes were applied with nitrogen serving as the desolvation gas and the collision gas.
The parameters for detection of lipids were as follows: Curtain Gas: 35; CAD: High; Ion Spray Voltage:
4500 V; Source Temperature: 350 ◦ C; Gas 1: 60; Gas 2: 60; Declustering Potential: +/−80 V, and collision
energies +/−10.
2.5. Metabolites: GC-MS Conditions
A Leco Pegasus IV time of flight mass spectrometer coupled with Agilent 6890 GC equipped with
a Gerstel automatic liner exchange system (ALEX) that included a multipurpose sample (MPS2) dual
rail, and a Gerstel CIS cold injection system (Gerstel, Muehlheim, Germany) was used to complement
HILIC metabolite analysis. The transfer line was maintained at 280 ◦ C. Chromatography separation
was achieved on a 30 m long, 0.25 mm i.d. Rtx-5Sil MS column (0.25 µm 95% dimethyl 5% diphenyl
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polysiloxane film) with the addition of a 10 m integrated guard column was used (Restek, Bellefonte,
PA, USA) with helium (99.999%; Airgas, Radnor, PA, USA) at a constant flow of 1 mL/min. The oven
temperature was held constant at 50 ◦ C for 1 min and then ramped at 20 ◦ C/min to 330 ◦ C at which it
was held constant for 5 min. The GC temperature program was set as follows: 50 ◦ C to 275 ◦ C final
temperature at a rate of 12 ◦ C/s and hold for 3 min. The injection volume was 1 µL in splitless mode at
250 ◦ C. Electron impact ionization at 70 V was employed with an ion source temperature of 250 ◦ C.
The scan mass ranged from 85 to 500 Da with an acquisition rate of 17 spectra/second.
2.6. Statistical Analysis
Prior to statistical analysis, metabolomic and lipidomic data were subjected to preprocessing as
follows. Data were first normalized by a variant of a ‘vector normalization’ by calculating the sum of all
peak heights for all identified metabolites for each sample and thereafter normalizing each compound
by the total average of the sum. Multivariate statistical analysis tends to focus on metabolites with high
intensities. To avoid this tendency, log scaling was applied to reduce the effect of large peaks and scale
the data into a more normally distributed pattern. Pareto scaling, which uses the square root of the
standard deviation as the scaling to change the emphasis from metabolites with high concentrations to
those with moderate or small abundances, was also used for analyzing parameters with large variation.
The patient cohort was divided into patients that developed either acute or chronic GVHD
and patients that did not develop GVHD. Because of the small sample size and since the analysis
was performed before transplantation, autologous stem cell transplant patients that did not develop
GVHD were grouped with allograft recipients that also did not develop GVHD. Partial least squares
discriminant analysis (PLS-DA) was used to create a bilinear model to fit the data (Figure 1). Multivariate
statistical methods such as PLS-DA have been introduced to reduce the complexity of metabolic spectra
and help identify meaningful patterns in high-resolution mass spectrometric data. In this method,
the PLS-DA scores can be filtered through calculation of the variable importance in projection (VIP),
and used to estimate the contribution of lipids and metabolites for class separation. The top 20 most
important variables in the PLS-DA model were selected for further investigation (Figure 1).
Because of the relatively small sample size, cross validation was employed to further evaluate the
classification model performance. An algorithm based on support vector machine (SVM) was used to
identify the top 20 variable importance in projection (VIP) to further select the best hyperplane that
represents the largest separation between the two groups (Figure 1). This method was coupled with
Monte-Carlo cross validation (MCCV) through balanced subsampling to support the validation in
the small sample cohort (Figure 1). In each MCCV, two thirds of the samples are used to evaluate
the feature importance and the remaining one-third is used as test population. The SVM and MCCV
allows a multivariate area under the curve of the receiver operating characteristic (AUCROC) analyses
to estimate the success of the classification model (Figure 1), creating several AUCROC models to test
performances with different numbers of predictors. This procedure was repeated multiple times to
calculate the performance estimates and build a confidence interval for each model. Based on the
performance in the multivariate AUCROC, the best number of predictors is a reference for selection of
potential biomarkers [27].
Univariate AUCROC analyses was used to find potential biomarkers with sufficient power to
separate the groups (Figure 1). The result shows the t-test p-value and the AUCROC value with the
confidence interval computed using 500 bootstrap replications. The criteria to choose the stronger
potential biomarkers for GVHD was to select compounds with the highest AUCROC performance and
lowest p-value (p < 0.05). The calculated optimal cutoff was used to estimate the associated sensitivity
and specificity values. Positive and negative likelihood ratios are calculated from the sensitivity and
specificity output. The data were analyzed using MetaboAnalyst 3.5 maintained by Xia Lab at McGill
University. The statistical approach outlined here (Figure 1) was designed to provide meaningful and
validated results optimized for the small sample size of the cohort, aiming to find potential biomarkers
of GVHD to support future studies. To obtain an adequately powered sample size, patients who
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Table 2. The metabolites and lipids constituting the top 20 VIP’s that predict class separation on
the day of transplant between those patients who eventually went on to develop GVHD as opposed
to those who did not develop GVHD following SCT. Patients that went onto develop GVHD had
decreased 2-aminobutyric acid, hexose, unsaturated fatty acids, and plasmenyl-ethanolamine PE (p-34:1)
or PE (o-34:2), along with elevated monoacylglycerols and diacylglycerols, lysophosphocholines,
phosphocholines. and phosphoethanolamines. GVHD’ patients (YES) and non-GVHD (NO) are
represented by dark grey (high) or light grey (low), respectively.
Class

Predictors

VIP

Alpha-amino acid
Monosaccharide

2-aminobutyric acid
Hexose
1-monoolein
1-monopalmitin
DG 38:5
DG 38:6
FA 14:1
FA 16:1
FA 18:1
FA 19:1
FA 20:1
FA 20:3
LPC 14:0
LPC 20:0
PC 28:0
PC 14:0/16:1
PC 16:0/18:3
PE 16:0/18:1
PE 18:0/22:5
PE (p-34:1) or PE (o-34:2)

1.80
2.67
2.11
2.54
1.97
1.91
1.90
2.08
1.92
2.09
2.01
2.07
2.79
2.46
2.29
1.95
1.95
2.02
2.23
1.75

Monoacylglycerol
Diacylglycerol

Fatty acid

Lysophosphatidylcholine
Phosphatidylcholine
Phosphatidylethanolamine
Plasmenyl-ethanolamine

GVHD
NO

YES

3.2. The More Important Variables for Class Separation Suggest Metabolic Pathway Tendencies Predispoising
to Alloreactivity
So far, our study has identified 20 metabolites, the presence of which correlates with the eventual
development of GVHD, suggesting an inherent metabolic disturbance that predisposes a patient
towards alloreactivity as early as the day of SCT. Further examination of these metabolites indicates that
they modulate three related metabolic pathways. Activated phospholipid metabolism appears to be one
of the main alterations associated with GVHD pre-transplant. 1-monopalmitin is a monoacylglycerol
that had a high VIP score (2.54), and its elevation in the GVHD group indicates phospholipid
degradation in cell membranes to produce diacylglycerol, the precursor for MAGs. Alternatively,
the non-GVHD state appears to be associated with elevation of monounsaturated and polyunsaturated
fatty acids (Figure 3A). Hexose, more commonly called glucose, also had a high VIP score (2.67),
indicating that elevated glucose uptake is on demand for energy production in the tricarboxylic
acid cycle (TCA), as well as increased aerobic glycolysis required for hematopoietic cell proliferation.
These processes increase the production of the reduced form of nicotinamide adenine dinucleotide
(NADH) used in the electron transport chain, but its upregulation induces excessive reducing power
that triggers processes such as fatty acid unsaturation and ROS production (Figure 3B). The levels of
oxidative stress originated by excessive ROS production is controlled by the glutathione metabolism,
where NADH is also used to reduce glutathione for its antioxidant action over ROS. The excessive
demand for antioxidative process can deplete glutathione and its precursor cysteine, increasing the
demand of 2-aminobutyric acid that can either modulate the glutathione synthesis or be used in
ophtalmate synthesis, a tripeptide analog of glutathione, with similar compensative antioxidative
actions (Figure 3C).

Cancers 2019, 11, 1051

9 of 17

Cancers 2019, 11, x

9 of 17

Figure 3.
3. The
Themore
moreimportant
importantlipids
lipidsand
andmetabolites
metabolites associated
associated with
with GVHD
GVHD may
may indicate
indicate the
the main
main
Figure
compensatory
metabolic
pathways
modulated
in
hematopoietic
cells
pre-transplant.
(A)
Phospholipids
compensatory metabolic pathways modulated in hematopoietic cells pre-transplant. (A)
metabolism are metabolism
affected suggesting
Phospholipase
C activity
to produceC diacylglycerols
(DAGs),
Phospholipids
are affected
suggesting
Phospholipase
activity to produce
and
diacylglycerol
lipase
and
monoacylglycerol
lipase
activity
to
produce
monoacylglycerols
diacylglycerols (DAGs), and diacylglycerol lipase and monoacylglycerol lipase activity to produce
(MAGs) and free fatty
acids (FFA),
monounsaturated
(MUFA) and
monoacylglycerols
(MAGs)
and respectively.
free fatty Predominance
acids (FFA), of
respectively.
Predominance
of
polyunsaturated
(PUFA)
free
fatty
acids
are
result
of
increased
fatty
acyl-CoA
desaturases
activity,
monounsaturated (MUFA) and polyunsaturated (PUFA) free fatty acids are result of increased
fatty
increasingdesaturases
the anticancer
activityincreasing
of ω-3 fatty
acids.
This metabolic
is linked
elevated
levels
acyl-CoA
activity,
the
anticancer
activity pathway
of ω-3 fatty
acids.toThis
metabolic
of the reduced
formtoofelevated
nicotinamide
dinucleotide
produced
in the tri-carboxylic
pathway
is linked
levelsadenine
of the reduced
form(NADH),
of nicotinamide
adenine
dinucleotide
acid
cycle
(TCA),
and
important
on
desaturases
activity.
(B)
Glucose
uptake
is increased
due(B)
to
(NADH), produced in the tri-carboxylic acid cycle (TCA), and important on desaturases
activity.
increased
energy
demands
in
hematopoietic
cells,
and
increased
aerobic
glycolysis
with
increased
Glucose uptake is increased due to increased energy demands in hematopoietic cells, and increased
NADH,glycolysis
providingwith
NADH
for the electron
andfor
resulting
in reactive
oxygen
species
aerobic
increased
NADH, transport
providingchain
NADH
the electron
transport
chain
and
(ROS).
(C)
Oxidative
stress
compensation
is
achieved
by
activation
of
cysteine-glutathione
pathway,
resulting in reactive oxygen species (ROS). (C) Oxidative stress compensation is achieved by
and antioxidant action. Exacerbation of these mechanism leads to depletion of cysteine and glutathione,
activation
of cysteine-glutathione pathway, and antioxidant action. Exacerbation of these mechanism
causing increased 2-aminobutyric acid-ophtalmate compensatory pathway activation originated from
leads to depletion of cysteine and glutathione, causing increased 2-aminobutyric acid-ophtalmate
amino acids metabolism.
compensatory pathway activation originated from amino acids metabolism.

3.3. The More Important Variables for Class Separation Can Be Used to Build Models for GVHD Association
3.3. The More Important Variables for Class Separation Can Be Used to Build Models for GVHD Association
To evaluate the potential to build models to possibly predict future GVHD, the top 20 highest VIP
To
evaluate
potential
to build
models
to possibly
predict
futurethat
GVHD,
themetabolites
top 20 highest
scores were
used the
in an
exploratory
analysis.
Hence,
the analysis
showed
plasma
and
VIP
scores
were
used
in
an
exploratory
analysis.
Hence,
the
analysis
showed
that
plasma
lipids obtained post-conditioning on day 0 prior to SCT, may be used to build predictivemetabolites
models for
and
lipids
obtained
post-conditioning
day 0 prior
to SCT, may
besame
usedlevel
to build
predictive models
GVHD
(Figure
4). Models
with 2, 3, or on
5 variables
demonstrated
the
of performance,
fitting
for
GVHD
(Figure
4).
Models
with
2,
3,
or
5
variables
demonstrated
the
same
level
of
performance,
the selection criteria, with AUCROC ranging from 0.915 to 0.935. With the criteria of finding the lowest
fitting
the
ranging
from the
0.915
to 0.935.profile
With of
thethe
criteria
of afinding
number
of selection
predictorscriteria,
that canwith
alsoAUCROC
physiologically
explain
metabolic
classes,
model
the
number was
of predictors
can exploration
also physiologically
explain
the metabolic
profile of the
withlowest
five predictors
chosen forthat
further
as potential
biomarkers
for risk stratification
of
classes,
a
model
with
five
predictors
was
chosen
for
further
exploration
as
potential
biomarkers
for
patients with the potential for development of GVHD following SCT.
risk stratification of patients with the potential for development of GVHD following SCT.

Cancers 2019, 11, 1051
Cancers 2019, 11, x

10 of 17
10 of 17

Figure 4. The top 20 variables from PLS-DA method were used to build appropriate classification
Figure 4. The top 20 variables from PLS-DA method were used to build appropriate classification
models with their respective confidence interval. Predictive models pre-transplant demonstrated robust
models with their respective confidence interval. Predictive models pre-transplant demonstrated
classification even with only two variables.
robust classification even with only two variables.
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Table 3. Potential biomarkers performance for a model with top five predictors based on accuracy
Predictor
AUC
p-Value
Sensitivity
Specificity
LR+
LR−
performance (area under the curve (AUC) estimate).
0.96
0.86
1.00
1-monopalmitin
0.0005
infinity
0.14
Predictor (0.82–1.00)AUC
p-Value (0.71–1.00)
Sensitivity (1.00–1.00)
Specificity
LR+
LR−
0.96

0.86

1.00

0.96
0.86
0.86
0.0005
(0.82–1.00) 0.003
(0.71–1.00)
(1.00–1.00)
(0.80–1.00)
(0.57–1.00)
(0.64–1.00)

1-monopalmitin

DG 38:5

0.96
DG 38:5
0.86 (0.80–1.00)
DG 38:6
0.035
(0.57–1.00) 0.86
DG 38:6
2-aminobutyric
0.86 (0.57–1.00)
0.029
acid
(0.61–1.00) 0.86
2-aminobutyric
acid
(0.61–1.00)
0.82
0.82
FA 20:1FA 20:1
0.039
(0.49–0.97)
(0.49–0.97)

0.003
0.035
0.029
0.039

0.86
0.86
0.86
0.86
(0.57–1.00)
(0.64–1.00)
(0.43–1.00)
(0.64–1.00)
0.86
0.86
(0.43–1.00)
(0.64–1.00)
0.86
0.71
0.86
0.71
(0.57–1.00)
(0.29–1.00)
(0.57–1.00)
(0.29–1.00)
1.00 1.00
0.570.57
(1.00–1.00)
(1.00–1.00) (0.29–0.86)
(0.29–0.86)

infinity

0.14

6.0

0.17

6.0
6.0

6.0

3.0

3.0

2.32.3

0.17
0.17

0.17

0.20

0.20

0.00
0.00
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4. Discussion
The identification of biomarkers that might enable the risk stratification of SCT patients with
respect to the potential for development of GVHD has significant clinical utility in the execution of
SCT protocols [28–30]. We have previously demonstrated that combined lipidomics and metabolomics
approached are extremely useful in identifying putative metabolic biomarkers of disease [31]. Here, we
demonstrate the discovery of 18 lipids and 2 metabolites separating the GVHD from the non-GVHD
cohorts, also implicating specific metabolic pathways involved in the pathogenesis of alloreactivity.
2-aminobutyric acid is a byproduct in the cysteine biosynthesis pathway and relates to glutathione
(GSH) metabolism. The presence of an alpha-amino acid as a predictor of GVHD after SCT is
substantiated by the reported role of amino acid metabolic changes pre-transplantation [32]. Moreover,
Reikvam et al. [33] showed that the altered metabolism of branched chain amino acids, as well as of
isobutyryl-carnitine and propyonyl-carnitinine in lipids, before pre-conditioning are associated with
the development of acute GVHD. Our results suggest that even as early as after conditioning therapy
and before transplantation, the effects of amino acid and lipid metabolism may be associated with
GVHD onset.
The metabolic implication of 2-aminobutyric acid in modulation of GSH homeostasis by production
of ophthalmic acid is also well known [34]. Ophtalmate is an analog of GSH in which the cysteine group is
replaced by L-2-aminobutyrate. It has been proposed that oxidative stress leads to intracellular depletion
of GSH, depletion of cysteine, and consequent activation of ophthalmate synthesis [35]. 2-aminobutiric
acid increases intracellular GSH levels by regulation of AMP-activated protein kinase and increase of
the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH). Moreover, it has been
demonstrated that chemotherapy agents are capable of inactivating glutathione reductase, the enzyme
that catalyzes the reduction of glutathione disulfide to the sulfhydryl form glutathione [36,37].
Particularly in the immune system, activated T cells undergoing clonal expansion have increased
energy demands that increase production of ROS by the mitochondrial electron transport chain [38].
GSH is not necessary for cell activation, but activated T cells regulate their oxidative stress by using
GSH, a key component for metabolic reprograming for cell differentiation [39]. Also, TCR ligation and
binding with costimulatory molecules induces metabolic remodeling of the naive T cell to anabolic
growth and biomass accumulation, and increases aerobic glycolysis [40].
A novel observation from the metabolic profile of GVHD-prone patients in our study is that
monoacylglycerol (MAG), diacylglycerol (DAG), fatty acids, phospholipids, and plasmalogens
metabolism are significantly altered, identifying lipids as potential mediators of GVHD. Lipid
modulation is expected due to metabolic demands of compromised hematopoietic tissue, immunologic
response, and underlined inflammatory profile of the patients related to the conditioning regimen.
The effects of MUFA and PUFA from the omega-3 family in decreasing inflammation have been
extensively studied in efforts to introduce intake of dietary lipids toward treatment of several
diseases [41]. These lipids have the potential to decrease production of cytokines in response to LPS
and increase the concentration of the anti-inflammatory cytokine IL-10 [42]. The ratio of saturated
to monounsaturated fatty acids in membrane phospholipids is critical to normal cellular function.
Alterations in this ratio have been correlated with cancer, and the oxidative stress characteristic of the
pathology [43,44].
In a study analyzing plasma phospholipids changes in patients with acute leukemia, it was
demonstrated that all phospholipids’ concentrations found in patients at the time of diagnosis
were significantly lower than in the reference group [45]. Endogenous lipids are important not
only in regulation of inflammation, but also in expressing antitumor functions in several types
of cancer [46–48]. Free fatty acids may be esterified in cell membrane phospholipids undergoing
hydrolysis by phospholipases to generate bioactive lipid mediators, including lysophosphocholine
(LPC), diacylglycerol (DAG), monoacylglycerol (MAG), and unsaturated fatty acids (MUFA and PUFA).
LPC is known to exert immune-regulatory activity by increases in the numbers of T cells, monocytes
and neutrophils, and also inducing protein kinase C activation in bone marrow derived mast cells [45].
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DAGs are not only a precursor for free fatty acids but also an important signaling molecule in cells.
Protein kinase C (PKC) is the major cellular target of DAG. The protein kinase D (PKD) is a substrate
of PKC responsible for several cell responses as proliferation, differentiation, apoptosis, and immune
response through TCR signaling [49]. Under oxidative stress, ROS induces activation of PKD to protect
the cell from oxidative-stress-induced cell death [50].
1-monopalmitin is a MAG formed via release of a fatty acid from DAG by diacylglycerol lipase.
The hydrolysis of MAG to FFA and glycerol is conducted by the MAG lipase (MAGL) in different
tissues, although ABHD6, a MAG hydrolase, has also been implicated in the pathogenesis of metabolic
syndrome [51], inflammation [52], and in cancer [53]. Deletion or inhibition of ABHD6 activity
has been shown to be beneficial in certain cancers [54]. The importance of 1-monoacylglycerols
with a saturated fatty acid group is demonstrated by its accumulation upon ABHD6 suppression,
and direct binding to the ligand binding domain of the peroxisome proliferator-activated receptors
PPARα and PPARγ, and activating these transcription factors [55]. MAGs metabolism is also related
to the effects of endocannabinoids in the immune system. The endocannabinoid receptor CB2 is
identified as a peripheral receptor preferably present in B cells, T cells, macrophages, monocytes,
natural killers, and polymorphonuclear. The enzyme MAGL that hydrolyzes MAGs also hydrolyzes
2-arachidonoylglycerol (2-AG), an endogenous endocannabinoid acting through CB2 receptors in the
immune system with immune suppression effects [56,57].
5. Limitations
The small size of the cohort used in this study is a limitation that prevents definitive confirmation
that the biomarkers identified in this study may be used as predictors to risk stratifying patients with
respect to the potential for the development of GVHD. The small sample size also compelled us to
combine patients with acute and chronic GVHD, to look at cumulative GVHD incidence and to pool
autologous SCT controls with those allograft recipients who did not experience GVHD. Despite these
limitations, this study allows an understanding of the metabolic milieu in the study population at the
time of transplantation and can be used to direct future studies similar to other studies described in
literature [58]. Furthermore, significance following the use of the statistical strategy to overcome the
small sample size using Monte Carlo cross validation with bootstrap resampling to create confidence
intervals further indicate the study results are of significance. Such approaches have been used
previously in the literature as appropriate tools to deal with the small sample size problem [59].
6. Conclusions
Our study demonstrates that the pre-transplant lipidome and the metabolome of SCT recipients
has significant potential towards their risk stratification with respect to the development of GVHD,
indicating potential use as biomarkers for this purpose. The identified potential biomarkers indicate a
pro-inflammatory metabolic profile in patients that will eventually develop GVHD. The role of GSH
and its association with 2-aminobutyric acid, coupled with signs of altered glucose metabolism, support
the hypothesis that in patients that will develop GVHD, GSH levels are excessively depleted due to
elevated oxidative stress related to glucose metabolism, in response to chemotherapy treatment. In this
scenario, both groups have elevated 2-aminobutyric acid as a compensatory mechanism, although in
patients susceptible to develop GVHD, it is not produced in a large enough amount to compensate
for the increased antioxidant demand. Furthermore, the decreased levels of plasma hexose indicate
excessive glucose uptake for glycolysis, oxidative phosphorylation, and consequent ROS production.
The protective effect of MUFA and PUFA as anti-inflammatory agents is decreased in patients that will
develop GVHD, and elevation of phospholipids and DAG and MAG indicates an increased traffic of
inflammatory lipids. This pro-inflammatory profile in patients with risk of GVHD is associated with
immune suppression, and characterize an unfavorable environment coupled with the overwhelming
physiologic impact of undergoing the donor graft, predisposing the host to GVHD.
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